Company Description
Silk Road Medical, Inc operates as a medical device company in the United States.
The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR).
Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.
The company was incorporated in 2007 and is headquartered in Sunnyvale, California. As of September 17, 2024, Silk Road Medical, Inc operates as a subsidiary of Boston Scientific Corporation.
| Country | United States |
| Founded | 2007 |
| IPO Date | Apr 4, 2019 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 474 |
| CEO | Charles McKhann |
Contact Details
Address: 1213 Innsbruck Drive Sunnyvale, California 94089 | |
| Phone | 408 720 9002 |
| Website | silkroadmed.com |
Stock Details
| Ticker Symbol | SILK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001397702 |
| CUSIP Number | 82710M100 |
| ISIN Number | US82710M1009 |
| Employer ID | 20-8777622 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Charles S. McKhann | Chief Executive Officer and Director |
| Lucas W. Buchanan | Chief Financial Officer and Chief Operating Officer |
| Kevin M. Klemz | Executive Vice President, Chief Legal Officer and Secretary |
| Erica J. Rogers | Independent Consultant |
| Andrew S. Davis | Chief Commercial Officer |
| Richard M. Ruedy | Executive Vice President of Clinical, Regulatory Affairs and Quality Assurance |
| Mhairi L. Jones | Chief Accounting Officer and Vice President of Finance |
| Tammy Leitsinger | Compliance Officer and Vice President of Medical Affairs |
| Jorge O'Hara | Vice President of Marketing, Business Development and Strategy |
| Alison Highlander | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 27, 2024 | 15-12G | Securities registration termination |
| Sep 23, 2024 | EFFECT | Notice of Effectiveness |
| Sep 19, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 17, 2024 | 25-NSE | Filing |
| Sep 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Sep 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |